Jonathan E Rosenberg

Jonathan E Rosenberg

UNVERIFIED PROFILE

Are you Jonathan E Rosenberg?   Register this Author

Register author
Jonathan E Rosenberg

Jonathan E Rosenberg

Publications by authors named "Jonathan E Rosenberg"

Are you Jonathan E Rosenberg?   Register this Author

100Publications

4153Reads

24Profile Views

The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.

Eur Urol 2019 03 28;75(3):435-444. Epub 2018 Sep 28.

Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.09.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697269PMC
March 2019

Refining existing knowledge and management of bladder cancer.

Nat Rev Urol 2019 02;16(2):75-76

Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41585-018-0137-3DOI Listing
February 2019

EMA and FDA prune the checkpoint inhibitor treatment landscape.

Nat Rev Urol 2018 Oct;15(10):596-597

Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41585-018-0074-1DOI Listing
October 2018

Reply to S. Zhang et al.

J Clin Oncol 2018 10 5;36(30):3057-3058. Epub 2018 Sep 5.

Min Yuen Teo, Kenneth Seier, Irina Ostrovnaya, and Jonathan E. Rosenberg, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.3026DOI Listing
October 2018

Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.

J Clin Oncol 2018 07 9;36(19):1949-1956. Epub 2018 May 9.

Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E. Arcila, Jamie C. Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Brooke E. Kania, Mariel E. Boyd, Catharine K. Cipolla, Ashley M. Regazzi, Asia S. McCoy, Hebert Alberto Vargas, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center; Gopa Iyer, Bernard H. Bochner, Guido Dalbagni, S. Machele Donat, Harry W. Herr, Hikmat Al-Ahmadie, David B. Solit, and Dean F. Bajorin, Weill Cornell Medical College; Arjun V. Balar, William C. Huang, Samir S. Taneja, and Daniela Delbeau, New York University Langone Medical Center, New York, NY; and Matthew I. Milowsky, Michael Woods, Tracy L. Rose, and William Y. Kim, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.0158DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6049398PMC
July 2018

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.

J Clin Oncol 2018 06 28;36(17):1685-1694. Epub 2018 Feb 28.

Min Yuen Teo, Kenneth Seier, Irina Ostrovnaya, Ashley M. Regazzi, Brooke E. Kania, Meredith M. Moran, Catharine K. Cipolla, Mark J. Bluth, Joshua Chaim, Alexandra Snyder, Maria I. Carlo, Michael F. Berger, Samuel Funt, Jedd D. Wolchok, Margaret K. Callahan, and Jonathan E. Rosenberg, Memorial Sloan Kettering Cancer Center; and Hikmat Al-Ahmadie, David B. Solit, Gopa Iyer, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.7740DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366295PMC
June 2018

Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.

Urol Clin North Am 2018 May;45(2):287-295

Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ucl.2017.12.011DOI Listing
May 2018

Global Cancer Transcriptome Quantifies Repeat Element Polarization between Immunotherapy Responsive and T Cell Suppressive Classes.

Cell Rep 2018 Apr;23(2):512-521

Tisch Cancer Institute, Departments of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Oncological Sciences and Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Precision Immunology Institute at the Icahn School of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2018.03.042DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016853PMC
April 2018

Nivolumab for the treatment of urothelial cancers.

Expert Rev Anticancer Ther 2018 03 31;18(3):215-221. Epub 2018 Jan 31.

a Department of Medicine, Division of Solid Tumor Oncology, Genitourinary Oncology Service , Memorial Sloan Kettering Cancer Center , New York , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2018.1432357DOI Listing
March 2018

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.

J Urol 2017 09 26;198(3):552-559. Epub 2017 Apr 26.

American Urological Association Education and Research, Inc., Linthicum, Maryland; American Society of Clinical Oncology, Alexandria, Virginia; American Society for Radiation Oncology, Arlington, Virginia; Society of Urologic Oncology, Inc., Schaumburg, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2017.04.086DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626446PMC
September 2017

Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary.

J Oncol Pract 2017 09 10;13(9):621-625. Epub 2017 Aug 10.

Vanderbilt University Medical Center, Nashville, TN; Memorial Sloan Kettering Cancer Center, New York, NY; Oregon Health & Science University School of Medicine, Portland, OR; University of Virginia, Charlottesville, VA; MD Anderson Cancer Center; Baylor College of Medicine, Houston; UT Southwestern, Dallas, TX; Northwestern University, Chicago, IL; Washington University School of Medicine, Saint Louis, MO; University of Michigan, Ann Arbor, MI; Bladder Cancer Advocacy Network, Bethesda, MD; Massachusetts General Hospital, Salem, MA; and Kansas University Medical Center, Kansas City, KS.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2017.024919DOI Listing
September 2017

Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.

Nat Rev Clin Oncol 2017 04 22;14(4):221-234. Epub 2016 Nov 22.

Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2016.188DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6054138PMC
April 2017

Circulating biomarkers to guide systemic therapy for urothelial carcinoma.

Urol Oncol 2016 11 15;34(11):502-509. Epub 2016 Oct 15.

Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2016.08.019DOI Listing
November 2016

Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma.

Clin Genitourin Cancer 2016 Feb 7;14(1):e81-90. Epub 2015 Aug 7.

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2015.07.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5003615PMC
February 2016

Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?

Eur J Cancer 2016 Jan 15;53:96-104. Epub 2015 Dec 15.

GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.10.006DOI Listing
January 2016

Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma.

Bladder Cancer 2016 Jan 7;2(1):111-117. Epub 2016 Jan 7.

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/BLC-150038DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927849PMC
January 2016

Treatment Decision Making in Patients with Bladder Cancer.

Bladder Cancer 2015 Oct 26;1(2):151-158. Epub 2015 Oct 26.

Division of Urologic Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/BLC-150029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927892PMC
October 2015

Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma.

Clin Genitourin Cancer 2015 Oct 5;13(5):410-20. Epub 2015 Mar 5.

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2015.02.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561017PMC
October 2015

Novel molecular targets for urothelial carcinoma.

Expert Opin Ther Targets 2015 Apr 30;19(4):515-25. Epub 2015 Jan 30.

Weill Cornell Medical College, Division of Hematology and Medical Oncology, Department of Medicine , New York, NY , USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728222.2014.987662DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4406627PMC
April 2015

First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients.

Hematol Oncol Clin North Am 2015 Apr 15;29(2):319-28, ix-x. Epub 2014 Dec 15.

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2014.10.005DOI Listing
April 2015

The role of genomics in the management of advanced bladder cancer.

Curr Treat Options Oncol 2015 Jan;16(1):319

Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center School of Medicine and Dentistry, 601 Elmwood Ave, Box 704, Rochester, NY, 14642, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007%2Fs11864-014-03
Web Search
http://link.springer.com/10.1007/s11864-014-0319-z
Publisher Site
http://dx.doi.org/10.1007/s11864-014-0319-zDOI Listing
January 2015

Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye.

J Clin Oncol 2014 Dec 10;32(36):4171-2. Epub 2014 Nov 10.

Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.5281DOI Listing
December 2014

Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.

Cancer Discov 2014 Sep 16;4(9):1014-21. Epub 2014 Jun 16.

Department of Medicine, University of California, San Francisco, California. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California. Department of Epidemiology and Biostatistics, University of California, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-14-0380DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155059PMC
September 2014

Optimal treatment for metastatic bladder cancer.

Curr Oncol Rep 2014 Sep;16(9):404

Division of Hematology and Medical Oncology, Mayo Clinic Cancer Center, 13400 E Shea Blvd, Scottsdale, AZ, 85259, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-014-0404-2DOI Listing
September 2014

Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.

J Clin Oncol 2014 Jun 12;32(18):1889-94. Epub 2014 May 12.

Toni K. Choueiri, Susanna Jacobus, Joaquim Bellmunt, Angela Qu, Edward C. Stack, Sabina Signoretti, Meghara Walsh, Graeme Steele, Michelle Hirsch, Christopher J. Sweeney, Mary-Ellen Taplin, Adam S. Kibel, Katherine M. Krajewski, Philip W. Kantoff, Robert W. Ross, and Jonathan E. Rosenberg, Dana-Farber Cancer Institute and Brigham and Women's Hospital; Christopher Tretter, Lahey Clinic, Burlington; Glenn J. Bubley, Beth Israel Deaconess Medical Center, Boston, MA; Leonard J. Appleman, University of Pittsburgh, Pittsburgh, PA; and Jonathan E. Rosenberg, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.52.4785DOI Listing
June 2014

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

Cancer Discov 2014 May 13;4(5):546-53. Epub 2014 Mar 13.

Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, 3Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; Departments of 4Medicine and 5Pathology, Brigham and Women's Hospital, Harvard Medical School; 6Division of Hematology/Oncology, Massachusetts General Hospital, Boston; 7Broad Institute of Harvard and MIT; 8Department of Biology, Whitehead Institute for Biomedical Research; 9Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts; and 10Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0353DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122326PMC
May 2014